A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 16, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1087.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Insys Therapeutics, Inc. securities (NASDAQ:INSY) from February 23, 2016 through March 15, 2017, inclusive (the "Class Period") of the important May 16, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Insys investors under the federal securities laws. To join the Insys class action, go to http://rosenlegal.com/cases-1087.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Insys had overstated its 2015 net revenue; (2) Insys had misstated its sales allowances for 2016; (3) accordingly, Insys lacked effective internal controls over financial reporting; and (4) as a result, Insys's public statements were materially false and misleading at all relevant times. On March 15, 2017, Insys announced during after-hours trading that "[t]he Audit Committee of the Company's Board of Directors has been conducting an independent review of the Company's processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016." On this news, shares of Insys fell $0.49 per share or approximately 5% to close at $10.06 per share on March 16, 2017, damaging investors.